Nexalin Technology, Inc. (the “Company” or “Nexalin”) (NASDAQ:NXL, NXLIW))))) today announced that its second generation (Gen-2), 15 milliamp (mA) neurostimulation device, has been granted regulatory approval by the Sultanate of Oman’s Ministry of Health.
Mark White, CEO of Nexalin Technology, stated, “We are pleased to announce the approval to sell our Gen-2 neurostimulation device in Oman, which represents our first regulatory approval outside of China. Not only is Oman an important gateway to the Middle East, but we intend to seek, and expect to be granted, additional approvals in other markets around the world. We look forward to finalizing our first commercial distribution agreement in Oman within the coming weeks and commencing commercial sales soon thereafter. We are laser-focused on opening new international markets and securing commercial distribution partners to rapidly and cost-effectively scale the business. Given the growing body of clinical data published in China supporting the benefits of our non-invasive, drug-free device, I am more confident than ever that our technology will play an important role in helping to combat the global mental health epidemic.”
